HC Wainwright Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock Price

AnaptysBio (NASDAQ:ANAB) had its target price decreased by stock analysts at HC Wainwright from $59.00 to $52.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 57.15% from the stock’s current price. HC Wainwright also issued estimates for AnaptysBio’s Q1 2026 earnings at ($0.88) EPS, Q3 2026 earnings at ($1.35) EPS and Q4 2026 earnings at ($1.29) EPS.

Several other research analysts have also recently weighed in on ANAB. Wedbush restated an “outperform” rating and issued a $50.00 price objective on shares of AnaptysBio in a research report on Monday. Truist Financial boosted their price target on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday. Wall Street Zen upgraded shares of AnaptysBio from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Guggenheim raised their price objective on shares of AnaptysBio from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, Barclays initiated coverage on shares of AnaptysBio in a report on Monday, October 13th. They set an “overweight” rating and a $78.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $59.40.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $33.09 on Tuesday. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $40.96. The stock has a fifty day moving average of $29.56 and a 200 day moving average of $24.97. The firm has a market capitalization of $916.26 million, a price-to-earnings ratio of -11.73 and a beta of 0.16.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. The business had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. Equities analysts forecast that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AnaptysBio

A number of large investors have recently added to or reduced their stakes in the business. US Bancorp DE lifted its stake in AnaptysBio by 126.5% in the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 979 shares during the last quarter. Bessemer Group Inc. increased its holdings in shares of AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after buying an additional 1,292 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,377 shares during the period. Osaic Holdings Inc. lifted its stake in shares of AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 2,326 shares during the last quarter. Finally, Brooklyn Investment Group lifted its stake in shares of AnaptysBio by 1,779.9% in the 1st quarter. Brooklyn Investment Group now owns 6,373 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 6,034 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.